| Abstrakt: |
A report from the Institute for Cancer Research and Treatment (IRCCS) in Rome, Italy discusses the use of bridge therapies for advanced hepatocellular carcinoma, the most common primary liver tumor. The study evaluates the effectiveness of different therapies, such as sorafenib, transarterial chemoembolization, radiation therapy, and combination therapies, in improving overall survival and reducing de-listing for liver transplant. The researchers found that combination therapies showed the most promising results and could potentially become the standard treatment for patients with advanced hepatocellular carcinoma. The study also highlights the potential of immunotherapy in treating this type of cancer. [Extracted from the article] |
